Wed, January 11, 2012
Tue, January 10, 2012
Mon, January 9, 2012
Sun, January 8, 2012
Sat, January 7, 2012
Fri, January 6, 2012
Thu, January 5, 2012
Wed, January 4, 2012
Tue, January 3, 2012
Mon, January 2, 2012
Sat, December 31, 2011
Fri, December 30, 2011
Thu, December 29, 2011
Wed, December 28, 2011
Tue, December 27, 2011
Mon, December 26, 2011
Fri, December 23, 2011

NuPathe to Present at Biotech Showcase 2012


//health-fitness.news-articles.net/content/2012/ .. nupathe-to-present-at-biotech-showcase-2012.html
Published in Health and Fitness on Wednesday, January 4th 2012 at 13:27 GMT by Market Wire   Print publication without navigation


January 04, 2012 16:20 ET

NuPathe to Present at Biotech Showcase 2012

CONSHOHOCKEN, PA--(Marketwire - Jan 4, 2012) - NuPathe Inc. (NASDAQ: [ PATH ]), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that [ Jane Hollingsworth ], chief executive officer, will present a company overview at Biotech Showcase 2012 on Wednesday, January 11, 2012, at 2:00 p.m. EST. The conference is being held at the Parc 55 Wyndham Hotel in San Francisco, CA.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, [ www.nupathe.com ]. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on NuPathe's website for 90 days following the presentation.

About NuPathe
[ NuPathe ] Inc. ([ www.nupathe.com ]) is an emerging biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, [ NP101 ], is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: [ NP201 ] for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and [ NP202 ] for the long-term treatment of schizophrenia and bipolar disorder.



Publication Contributing Sources